Nonetheless the current work describes a protocol that could be useful in assessing a much broader variety of potential markers such as neuropeptide Y (NPY), previously shown by our group to be a correlate of ME/CFS severity [51]. The gene discussed is NPY; the disease is myalgic encephalomeyelitis/chronic fatigue syndrome.